Evaluating the Clinical and Economic Outcomes Associated with Poor Glycemic Control in People with Type 1 Diabetes in the Netherlands

Robert Gerald Jan Moes,1 Eline L Huisman,1 Samuel JP Malkin,2 Barnaby Hunt2 1Novo Nordisk BV, Alphen aan den Rijn, Netherlands; 2Ossian Health Economics and Communications, Basel, SwitzerlandCorrespondence: Barnaby Hunt, Ossian Health Economics and Communications GmbH, Bäumleingasse 20, Basel, 4051, Switzerland, Tel +41 61 271 6214, Email hunt@ossianconsulting.comIntroduction: Achieving and maintaining glycemic control is the cornerstone of type 1 diabetes management, with the aim of reducing the incidence of diabetes-related complications over the long term. However, many individuals fail to... Mehr ...

Verfasser: Moes RGJ
Huisman EL
Malkin SJP
Hunt B
Dokumenttyp: Artikel
Erscheinungsdatum: 2023
Reihe/Periodikum: ClinicoEconomics and Outcomes Research, Vol Volume 15, Pp 87-96 (2023)
Verlag/Hrsg.: Dove Medical Press
Schlagwörter: diabetes complications / glycemic control / health economics / netherlands / type 1 diabetes / Medicine (General) / R5-920 / Therapeutics. Pharmacology / RM1-950
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26802125
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doaj.org/article/7d81cffd3f774331aa0f08a6dc07845b